1. Group
  2. Focus Areas
  3. Healthy Living
  4. Roadmaps
  5. Biomedical Health
  6. Enabling tomorrow’s medicine

TNO works with public and private parties to create and implement innovative technologies that make the process of drug development – from laboratory to patient – more efficient. This will make it possible to cut development costs and to get drugs to patients sooner.

TNO is developing a range of technologies that span the entire drug development process.

Drug delopment process and the technologies to accelerate drug development

The screening and selection techniques used in the discovery of active substances for new candidate drugs are steadily improving. This makes it possible to spotlight the development of disease, right down to the level of RNA, thus paving the way for the discovery of new targets.

Using models that reflect processes in humans with increasing precision, we can more accurately predict the potential effect of a drug in the preclinical phase. One such ‘translational model’ is the organ-on-a-chip. These models can improve the efficiency of animal testing, leading to a reduction in its use.

Technologies to accelerate in drug development

In the early stages of a trial’s clinical phase, TNO creates and implements technologies that provide insight into the efficacy and safety of specific drug candidates in humans, and that feature high information density. One example would be the use of microtracer studies, in combination with Accelerator Mass Spectrometry (AMS). This provides detailed information on how a given substance is absorbed into the body and subsequently excreted. One tangible benefit of using AMS as a research tool is that it can shorten the development process for new drugs by two to three years.

For example, in the more advanced stages of drug development, TNO is working on 3D-printed oral dosage forms. This technology is paving the way for the development of tablets with unique properties, such as tunable release profiles or different release levels for each individual API (Active Pharmaceutical Ingredient). This facilitates the cost-effective, small-scale use of products during testing in the clinical phase, and their production after acceptance.

Get in touch

At which point in your product’s development process do you have the greatest need for innovative technologies? Do you have a question that cannot be resolved using current technologies? If so, then please get in touch.

Do you have any questions about drug development?

Please get in touch with Steven Erpelinck

Contact
Our work

Early collection of ADME data from human subjects for drug development

A drug’s absorption, distribution, metabolism, excretion (ADME), and Adverse Drug Reactions (ADRs) are often difficult to predict. At TNO we have developed in vitro and ex vivo platforms that can help... Read more
Our work

Preclinical predictive models improve drug development pathway

In preclinical settings, effective predictive tools and models can be used to improve the development pathway for new drugs. One potential benefit is reduced drug loss at a later stage of development.... Read more
Our work

Drug Target Profiling: Informed decision making for innovative therapeutic approaches

Understanding your drug target is where successful drug discovery begins. Support your target identification, target evaluation and target derisking with TNO’s concise and customizable target evaluation... Read more
TNO Insights

TNO’s translational models excel in preclinical research

13 June 2022
Accelerating drug development requires us to remove some key roadblocks that slow down the development process. And one of the key roadblocks is the lack of translatability between preclinical trials and... Read more
General

Aiming for fast, accurate preclinical and clinical trials

Pharma companies want it. Regulators want it. Patients certainly want it: faster, more accurate, less expensive drug development. But with all the complexity that drug development entails, how can we... Read more
Contact

Steven Erpelinck BSc. MBA

  • bioavailability
  • microdosing
  • AMS transporters
  • permeability
  • PBPK modeling

Send a question to Steven Erpelinck BSc. MBA

×
  •  *
  •  *
  •  *

  • You will automatically receive a copy of your question by email at the email address you provided.

Your question has been sent.

Sorry! Something unexpected happened. Please try again later.

Contact

Steven Erpelinck BSc. MBA

  • bioavailability
  • microdosing
  • AMS transporters
  • permeability
  • PBPK modeling

Send a question to Steven Erpelinck BSc. MBA

×
  •  *
  •  *
  •  *

  • You will automatically receive a copy of your question by email at the email address you provided.

Your question has been sent.

Sorry! Something unexpected happened. Please try again later.